万古霉素与达托霉素在门诊肠外抗菌治疗中的医疗资源利用及成本比较
: Comparison of Vancomycin and Daptomycin Health Care Utilization and Cost in Outpatient Parenteral Antimicrobial Therapy.
作者信息
Streifel Amber C, Luis Katie, Nakrani Monark, Yu Diana, Sikka Monica K, Varley Cara D, Douglass Alyse, Mayer Heather, Young Kathleen, Lewis James S
机构信息
Department of Pharmacy, Oregon Health & Science University, Portland, Oregon, USA.
Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
出版信息
Open Forum Infect Dis. 2024 Jul 25;11(8):ofae438. doi: 10.1093/ofid/ofae438. eCollection 2024 Aug.
Abstract
Vancomycin and daptomycin are frequently used in outpatient parenteral antimicrobial therapy (OPAT). We analyze health care utilization and cost to the health care system for vancomycin vs daptomycin in the outpatient setting and find that vancomycin results in significantly higher health care utilization and similar cost per course compared with daptomycin in OPAT.
摘要
万古霉素和达托霉素常用于门诊胃肠外抗菌治疗（OPAT）。我们分析了门诊环境中使用万古霉素与达托霉素时的医疗保健利用率及医疗保健系统成本，发现与达托霉素相比，万古霉素导致显著更高的医疗保健利用率，且在OPAT中每疗程成本相近。
相似文献
1
: Comparison of Vancomycin and Daptomycin Health Care Utilization and Cost in Outpatient Parenteral Antimicrobial Therapy.
Open Forum Infect Dis. 2024 Jul 25;11(8):ofae438. doi: 10.1093/ofid/ofae438. eCollection 2024 Aug.
2
Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study.
J Antimicrob Chemother. 2014 May;69(5):1407-15. doi: 10.1093/jac/dkt512. Epub 2014 Jan 6.
3
A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy.
Infect Control Hosp Epidemiol. 2018 Aug;39(8):947-954. doi: 10.1017/ice.2018.107. Epub 2018 Jun 12.
4
Inpatient Antibiotic Costs Associated With Switching From Vancomycin to Daptomycin for Outpatient Parenteral Antibiotic Therapy.
Hosp Pharm. 2022 Feb;57(1):17-19. doi: 10.1177/0018578720970466. Epub 2020 Nov 6.
5
Vancomycin or Daptomycin for Outpatient Parenteral Antibiotic Therapy: Does It Make a Difference in Patient Satisfaction?
Open Forum Infect Dis. 2021 Aug 30;8(8):ofab418. doi: 10.1093/ofid/ofab418. eCollection 2021 Aug.
6
Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin.
Clinicoecon Outcomes Res. 2013 Sep 16;5:447-57. doi: 10.2147/CEOR.S46991. eCollection 2013.
7
Antimicrobial stewardship in the outpatient parenteral antimicrobial therapy (OPAT) setting: the impact of prescription assessment by an infectious diseases specialist.
Braz J Infect Dis. 2021 Mar-Apr;25(2):101560. doi: 10.1016/j.bjid.2021.101560. Epub 2021 Mar 11.
8
Evaluation of Inpatient Antimicrobial Regimens for Readmitted Outpatient Parenteral Antimicrobial Therapy Patients Receiving Daptomycin or Ertapenem for Ease of Administration.
Open Forum Infect Dis. 2019 Nov 19;6(12):ofz496. doi: 10.1093/ofid/ofz496. eCollection 2019 Dec.
9
Recent Updates in Antimicrobial Stewardship in Outpatient Parenteral Antimicrobial Therapy.
Curr Infect Dis Rep. 2021;23(12):24. doi: 10.1007/s11908-021-00766-x. Epub 2021 Nov 9.
10
Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin.
J Antimicrob Chemother. 2009 Sep;64(3):447-53. doi: 10.1093/jac/dkp245. Epub 2009 Jul 7.
引用本文的文献
1
Are Oritavancin and Dalbavancin More Cost Effective for Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Medical Center?
Fed Pract. 2025 Jun;42(6):236-243b. doi: 10.12788/fp.0571. Epub 2025 Jun 17.
2
Incidence and risk factors for musculoskeletal adverse effects associated with daptomycin in patients receiving outpatient parenteral antimicrobial therapy.
Antimicrob Steward Healthc Epidemiol. 2025 Jul 31;5(1):e169. doi: 10.1017/ash.2025.10087. eCollection 2025.
本文引用的文献
1
Counting the Cost of Daptomycin Versus Vancomycin in Hospitalized Patients: A Cost Minimization Analysis.
Open Forum Infect Dis. 2024 Apr 18;11(5):ofae217. doi: 10.1093/ofid/ofae217. eCollection 2024 May.
2
Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.
Am J Health Syst Pharm. 2020 May 19;77(11):835-864. doi: 10.1093/ajhp/zxaa036.
3
Risk factors for readmission in patients discharged with outpatient parenteral antimicrobial therapy: a retrospective cohort study.
BMC Pharmacol Toxicol. 2018 Aug 6;19(1):50. doi: 10.1186/s40360-018-0240-3.
4
A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy.
Infect Control Hosp Epidemiol. 2018 Aug;39(8):947-954. doi: 10.1017/ice.2018.107. Epub 2018 Jun 12.
5
Rates of and Risk Factors for Adverse Drug Events in Outpatient Parenteral Antimicrobial Therapy.
Clin Infect Dis. 2018 Jan 6;66(1):11-19. doi: 10.1093/cid/cix733.
6
Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service.
Int J Antimicrob Agents. 2018 Jan;51(1):26-32. doi: 10.1016/j.ijantimicag.2017.03.016. Epub 2017 Jun 30.
7
Patient satisfaction in an outpatient parenteral antimicrobial therapy (OPAT) unit practising predominantly self-administration of antibiotics with elastomeric pumps.
Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1387-1392. doi: 10.1007/s10096-017-2944-5. Epub 2017 Mar 11.
8
Vascular access complications during outpatient parenteral antimicrobial therapy at home: a retrospective cohort study.
J Antimicrob Chemother. 2016 Feb;71(2):506-12. doi: 10.1093/jac/dkv344. Epub 2015 Oct 28.
9
Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study.
J Antimicrob Chemother. 2014 May;69(5):1407-15. doi: 10.1093/jac/dkt512. Epub 2014 Jan 6.
10
Vancomycin: a 50-year reassessment.
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S3-4. doi: 10.1086/491708.
Zotero 插件